Mauna Kea Technologies, Inc. (Formerly known as Cellvizio Inc.) Reports The Success Of ICCU 2014 And Announces The Implementation Of Several Institutional Training Programs On Optical Biopsy

Published: Apr 18, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (Euronext: MKEA, FR0010609263), leader in the Optical Biopsy market, announced today major progress in the adoption of Optical Biopsy around the world. While more than 260 physicians from 30 countries gathered in Opio, France, for two days to discuss results and lay out the roadmap for Optical Biopsy in Gastroenterology, Urology, Pulmonology, Pathology, Surgery and many other specialties, the company reports several key initiatives demonstrating the adoption of Optical Biopsy around the world.

Help employers find you! Check out all the jobs and post your resume.

Back to news